908 Devices (MASS)


Market Price (11/19/2026): $9.51 | Market Cap: $395.4 MilSector: Health Care | Industry: Life Sciences Tools & Services

908 Devices (MASS)


Market Price (11/19/2026): $9.51
Market Cap: $395.4 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more.

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -22 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 136x

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%

Key risks
MASS key risks include [1] its history of net losses and uncertain profitability, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more.
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -22 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -33%
3 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 136x
4 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 15%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%
6 Key risks
MASS key risks include [1] its history of net losses and uncertain profitability, Show more.

MASS in ETFs

Weight = MASS's share of each fund

VTI0.00%
IWM0.01%
AVUV0.04%
IWN0.02%
VTWO0.01%
SCHA0.01%
DFAS0.00%
IWV0.00%
+2 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/18/2026

Nov 16: down 5.6% in one day (S&P 500 down 1.9%)
The stock declined without specific company news as market headlines indicated Nvidia again pulled the overall market lower. Broader concerns around chip stocks also affected markets that day.

Down 28.6% from its Oct 28 high to Nov 16, up 3.6% since (S&P 500 down 4.2%)
The stock declined over this period primarily due to its third quarter earnings report on November 10, combined with wider market concerns about tech stocks. Significant drops occurred on October 30 amid tech bubble discussions, and also on November 2 without specific news.

Nov 10: down 13.2% on its earnings report (S&P 500 down 0.4%)
The stock declined after the company reported a Q3 diluted EPS loss of $0.11 and a net income loss of $5M. This move came even as 908 Devices achieved record revenue of $19M and reported a smaller loss than the Zacks Consensus Estimate.

Show more
Prices as of 11/18/2026

Nov 16: down 5.6% in one day (S&P 500 down 1.9%)
The stock declined without specific company news as market headlines indicated Nvidia again pulled the overall market lower. Broader concerns around chip stocks also affected markets that day.

Down 28.6% from its Oct 28 high to Nov 16, up 3.6% since (S&P 500 down 4.2%)
The stock declined over this period primarily due to its third quarter earnings report on November 10, combined with wider market concerns about tech stocks. Significant drops occurred on October 30 amid tech bubble discussions, and also on November 2 without specific news.

Nov 10: down 13.2% on its earnings report (S&P 500 down 0.4%)
The stock declined after the company reported a Q3 diluted EPS loss of $0.11 and a net income loss of $5M. This move came even as 908 Devices achieved record revenue of $19M and reported a smaller loss than the Zacks Consensus Estimate.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 18.9% change in MASS stock from 7/31/2026 to 11/18/2026 was primarily driven by a 16.5% change in the company's P/S Multiple.
(LTM values as of)731202611182026Change
Stock Price ($)8.019.5218.9%
Change Contribution By: 
Total Revenues ($ Mil)586613.8%
P/S Multiple5.15.916.5%
Shares Outstanding (Mil)3741-10.3%
Cumulative Contribution18.9%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/18/2026
ReturnCorrelation
MASS18.9% 
Market (SPY)-2.0%52.8%
Sector (XLV)11.9%11.5%

Fundamental Drivers

The 39.4% change in MASS stock from 4/30/2026 to 11/18/2026 was primarily driven by a 35.0% change in the company's P/S Multiple.
(LTM values as of)430202611182026Change
Stock Price ($)6.839.5239.4%
Change Contribution By: 
Total Revenues ($ Mil)566617.1%
P/S Multiple4.45.935.0%
Shares Outstanding (Mil)3641-11.8%
Cumulative Contribution39.4%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/18/2026
ReturnCorrelation
MASS39.4% 
Market (SPY)2.1%49.4%
Sector (XLV)25.1%1.7%

Fundamental Drivers

The 19.3% change in MASS stock from 10/31/2025 to 11/18/2026 was primarily driven by a 22.6% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511182026Change
Stock Price ($)7.989.5219.3%
Change Contribution By: 
Total Revenues ($ Mil)546622.6%
P/S Multiple5.35.911.4%
Shares Outstanding (Mil)3641-12.6%
Cumulative Contribution19.3%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/18/2026
ReturnCorrelation
MASS19.3% 
Market (SPY)8.2%37.3%
Sector (XLV)27.7%6.0%

Fundamental Drivers

The 60.5% change in MASS stock from 10/31/2023 to 11/18/2026 was primarily driven by a 52.6% change in the company's P/S Multiple.
(LTM values as of)1031202311182026Change
Stock Price ($)5.939.5260.5%
Change Contribution By: 
Total Revenues ($ Mil)496634.2%
P/S Multiple3.95.952.6%
Shares Outstanding (Mil)3241-21.6%
Cumulative Contribution60.5%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/18/2026
ReturnCorrelation
MASS60.5% 
Market (SPY)81.1%23.1%
Sector (XLV)52.9%12.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
MASS Return-55%-71%47%-80%139%81%-83%
Peers Return39%-14%2%-4%1%22%44%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
MASS Win Rate33%33%50%33%50%64% 
Peers Win Rate78%43%52%52%47%55% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
MASS Max Drawdown-69%-73%-54%-83%-43%-29% 
Peers Max Drawdown-15%-32%-28%-25%-34%-29% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, TDY, BRKR, A, DHR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/18/2026 (YTD)

How Low Can It Go

EventMASSS&P 500
2025 US Tariff Shock
  % Loss-25.6%-18.8%
  % Gain to Breakeven34.3%23.1%
  Time to Breakeven1 days79 days
2024 Yen Carry Trade Unwind
  % Loss-11.9%-7.8%
  % Gain to Breakeven13.5%8.5%
  Time to Breakeven246 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-31.0%-9.5%
  % Gain to Breakeven44.9%10.5%
  Time to Breakeven19 days24 days
2023 SVB Regional Banking Crisis
  % Loss-44.3%-6.7%
  % Gain to Breakeven79.4%7.1%
  Time to Breakeven240 days31 days

Compare to TMO, TDY, BRKR, A, DHR

In The Past

908 Devices's stock fell -25.6% during the 2025 US Tariff Shock. Such a loss loss requires a 34.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventMASSS&P 500
2025 US Tariff Shock
  % Loss-25.6%-18.8%
  % Gain to Breakeven34.3%23.1%
  Time to Breakeven1 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-31.0%-9.5%
  % Gain to Breakeven44.9%10.5%
  Time to Breakeven19 days24 days
2023 SVB Regional Banking Crisis
  % Loss-44.3%-6.7%
  % Gain to Breakeven79.4%7.1%
  Time to Breakeven240 days31 days

Compare to TMO, TDY, BRKR, A, DHR

In The Past

908 Devices's stock fell -25.6% during the 2025 US Tariff Shock. Such a loss loss requires a 34.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About 908 Devices (MASS)

908 Devices Inc. (NASDAQ: MASS) is a commercial-stage technology company that develops and provides purpose-built mass spectrometry (Mass Spec) devices. These innovative devices are designed to analyze and understand unknown and invisible materials across a variety of scientific and industrial applications. The company focuses on bringing sophisticated analytical capabilities to the point-of-need, whether in the field or on the benchtop.

The company's primary product offerings include the MX908, a handheld, battery-powered Mass Spec device engineered for rapid identification of unknown gas, liquid, and solid materials. For laboratory settings, 908 Devices offers Rebel, a compact desktop analyzer that provides real-time insights into the extracellular environment crucial for bioprocesses. Additionally, the ZipChip solution is a plug-and-play, high-resolution separation platform designed to enhance and optimize Mass Spec sample analysis.

908 Devices serves a diverse range of customers and markets globally, including life sciences research, bioprocessing, industrial biotechnology, and forensics. The company operates across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, providing advanced analytical tools to professionals who require quick and accurate material identification and characterization.

AI Analysis | Feedback

Here are 1-3 brief analogies for 908 Devices (MASS):

The Thermo Fisher Scientific of advanced, accessible mass spectrometry.

The FLIR Systems for identifying unknown chemical and biological materials using mass spectrometry.

AI Analysis | Feedback

  • MX908: A handheld, battery-powered Mass Spec device for rapid analysis of unknown gas, liquid, and solid materials.
  • Rebel: A small desktop analyzer providing real-time information on the extracellular environment in bioprocesses.
  • ZipChip solution: A plug-and-play, high-resolution separation platform designed to optimize Mass Spec sample analysis.

AI Analysis | Feedback

908 Devices Inc. sells its specialized mass spectrometry devices primarily to other organizations and companies, rather than individuals. Based on the description, the company's major customers can be categorized into the following types of organizations, as specific company names are not provided in the background information:

  • Life Sciences Research & Biopharma Companies: This category includes pharmaceutical and biotechnology companies, academic research institutions, and contract research organizations (CROs). These customers utilize 908 Devices' technology for drug discovery, development, and various research applications, particularly the ZipChip solution and Rebel analyzer for optimizing sample analysis and real-time bioprocess information.
  • Bioprocessing & Industrial Biotech Organizations: Customers in this segment are involved in the manufacturing of biologics, cell and gene therapies, and other industrial applications of biotechnology. They rely on devices like the Rebel for monitoring and optimizing bioprocesses.
  • Forensic & Public Safety Agencies: This category encompasses government entities such as law enforcement agencies, homeland security, military units, and hazardous materials (hazmat) teams. They use devices like the MX908 for rapid, on-site analysis of unknown substances for security, safety, and investigative purposes.

AI Analysis | Feedback

null

AI Analysis | Feedback

Kevin J. Knopp, PhD

CEO & Co-founder

Kevin J. Knopp is the co-founder of 908 Devices, established in 2012, and has served as its CEO since February 2012, holding a tenure of over 14 years. His total yearly compensation was approximately $1.99 million as of September 30, 2025.

Joseph H. Griffith

Chief Financial Officer and Treasurer

Joseph H. Griffith serves as the Chief Financial Officer and Treasurer of 908 Devices. His total yearly compensation was approximately $1.24 million as of September 30, 2025.

Jon Frattaroli

VP, Strategy

Jon Frattaroli is the Vice President of Strategy at 908 Devices.

John Kenneweg

VP, Government

John Kenneweg holds the position of Vice President of Government at 908 Devices.

Kevin McCallion, PhD

VP, Products & Production

Kevin McCallion is the Vice President of Products & Production at 908 Devices. He joined the company in 2013, initially as the Director of Component Engineering. Prior to 908 Devices, he was the Vice President of Engineering for TeraDiode and the Director of Engineering at Finisar Corp. He also co-founded Azna LLC, where he served as the Vice President of Product Development. Dr. McCallion is an inventor on over 30 U.S. patents.

AI Analysis | Feedback

Here are the key risks to 908 Devices (MASS):
  1. History of Net Losses and Challenges to Achieve Profitability: 908 Devices has a history of net losses and faces significant challenges in achieving and maintaining profitability, as indicated by its negative operating and net margins. The company's financial health grades, including a low Piotroski F-Score and an Altman Z-Score in the distress zone, suggest poor business operations and a possibility of bankruptcy within the next two years. Additionally, the company has experienced negative free cash flow, highlighting ongoing cash flow challenges.
  2. Intense Competition and Need for Continuous Innovation: The company operates in the highly competitive medical devices and instruments industry. To remain competitive, 908 Devices must continuously innovate and adapt to rapid technological changes. A failure to develop new products or enhance existing ones could negatively impact market acceptance and its competitive position.
  3. Dependence on Limited Suppliers and Supply Chain Disruptions: 908 Devices relies on a limited number of suppliers for key components for its devices. This dependence poses risks of supply chain disruptions, which could adversely affect its operations, lead to reduced sales, and impact cash flows.

AI Analysis | Feedback

null

AI Analysis | Feedback

For 908 Devices (symbol: MASS), the addressable market for its main products has evolved following a strategic divestiture in March 2025.

  • MX908 (Handheld Devices): The total addressable market (TAM) for handheld devices, including the MX908, was estimated to be $1.5 billion globally at the time of 908 Devices' IPO in 2020. This market is projected to expand to $2.5 billion globally by 2027. This growth is driven by increasing worldwide concerns regarding illicit drugs, toxic industrial materials, and security threats, alongside software application extensions into GxP facilities for raw material inspection, counterfeit and adulteration detection, contamination and cleaning validation, and other quality assurance and quality control assays.
  • Rebel and ZipChip Solution: These products, which were part of 908 Devices' bioprocessing desktop portfolio, were divested to Repligen Corporation in March 2025. Therefore, the addressable markets for Rebel and ZipChip Solution are null for 908 Devices Inc.

AI Analysis | Feedback

908 Devices Inc. (MASS) is positioned for future revenue growth over the next 2-3 years, driven by several key factors:

  1. Accelerated Demand in Health, Safety, and Defense Technology Markets: The company is strategically focused on addressing critical issues such as the illicit drug crisis, toxic industrial materials, and global security threats. This focus is supported by increased U.S. funding to combat the illicit drug crisis and growing NATO defense budgets, driving demand for its handheld chemical detection tools.
  2. Growth from Recently Launched Products and Next-Generation Innovation: Strong demand for newly introduced products like VipIR and XplorIR is contributing significantly to revenue. Additionally, the anticipated commercial launch of a next-generation MX908 mass spectrometry platform in late 2026 is expected to open new customer opportunities and drive growth in 2027 and beyond.
  3. Contributions from the Department of Defense's AVCAD Program: The company's partnership with Smiths Detection on the Department of Defense's AVCAD program is nearing its next phase, with an initial production run expected in the second half of 2026. This program is projected to contribute $2 million-$3 million in 2026, with potential for over $10 million annually.
  4. Expansion of Recurring Revenue Streams: 908 Devices is actively increasing its recurring revenue, which includes consumables, accessories, software, and service revenue. This strategy, supported by new programs like the TeamLeader software platform, aims to grow recurring revenue to over 40% of total revenues from 35% in 2025, providing greater revenue visibility and predictability.
  5. Broadening Customer Base and International Expansion: The company is expanding its installed base of devices, which grew 24% year-over-year to 3,736 devices by the end of 2025. Growth in the U.S. state and local sales channel (up 38% in 2025) and increased international sales, particularly to NATO-aligned countries, are also key drivers.

AI Analysis | Feedback

Share Issuance

  • The company's common stock began trading on The Nasdaq Global Market on December 18, 2020.
  • The number of shares outstanding increased from 27,297,871 as of March 26, 2021, to 36,101,051 at the end of 2025.
  • As of March 11, 2026, the number of shares outstanding reached 37.38 million, representing a 5.35% increase in one year.

Outbound Investments

  • In August 2022, 908 Devices acquired Trace Analytics GmbH (later renamed 908 Devices GmbH), gaining microfluidic aseptic sampling technology for bioprocess applications.
  • The company acquired RedWave in April 2024, which expanded its product portfolio with FTIR technology.

Capital Expenditures

  • Capital expenditures were $4 million in 2022 and $4 million in 2023.
  • Capital expenditure was USD -955.0 thousand in 2025, marking a 58.6% decrease year-over-year.
  • In the last 12 months (prior to March 07, 2026), capital expenditures were $602K, primarily impacting free cash flow.

Better Bets vs. 908 Devices (MASS)

Peer Outperformance in Life Sciences Tools & Services

MASS has outperformed 56% of its 109 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that MASS has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
90%
of 125 industry peers · 77.9% return
3Y
75%
of 115 industry peers · 39.4% return
5Y
56%
of 109 industry peers · -64.7% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten MASS by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is MASS's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 20.4%83.0%196.8% CAH 525% · MCK 393% · COR 197%
Health Care Services 20 30.3%21.9%13.8% RDNT 157% · HIMS 130% · DGX 93%
Health Care Facilities 26 12.5%14.3%-7.7% THC 245% · NHC 223% · EHC 185%
Managed Health Care 8 56.6%-8.0%-9.8% OSCR 159% · HQY 55% · ELV 1%
Health Care Equipment 49 -0.4%5.4%-17.6% GKOS 394% · UFPT 358% · TMDX 319%
Health Care Supplies 11 24.2%1.3%-40.0% LNTH 252% · HAE 120% · MMSI 26%
Pharmaceuticals 60 -16.4%3.2%-41.7% LQDA 1121% · KNSA 653% · XERS 611%
Life Sciences Tools & Services ← 110 -19.2%-24.9%-75.1% AXGN 462% · MEDP 186% · NTRA 176%
Biotechnology 370 -33.9%-40.4%-84.4% ELVN 1240% · TRVI 1212% · DNTH 1117%
Health Care Technology 23 -20.6%-60.0%-86.6% VEEV -10% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1908 Devices Earnings Notes12/16/2025
2How Low Can 908 Devices Stock Really Go?10/17/2025
Title
0ARTICLES

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

MASSTMOTDYBRKRADHRMedian
Name908 Devi.Thermo F.Teledyne.Bruker Agilent .Danaher  
Mkt Price9.51695.49627.8363.28178.00227.70202.85
Mkt Cap0.4257.329.19.750.2160.339.6
Rev LTM6647,3516,5203,5137,37225,6086,946
Op Inc LTM-228,8631,3043321,6395,2181,472
FCF LTM37,5961,1482151,2675,7271,207
FCF 3Y Avg-197,1611,0381201,2575,2411,148
CFO LTM39,3241,2813421,6096,8591,445
CFO 3Y Avg-188,6921,1502341,6306,4881,390

Growth & Margins

MASSTMOTDYBRKRADHRMedian
Name908 Devi.Thermo F.Teledyne.Bruker Agilent .Danaher  
Rev Chg LTM23.7%8.3%8.6%2.2%8.6%5.5%8.4%
Rev Chg 3Y Avg11.9%3.0%5.1%7.8%2.0%6.9%6.0%
Rev Chg Q35.3%9.1%9.4%1.6%8.1%8.3%8.7%
QoQ Delta Rev Chg LTM8.1%2.2%2.3%0.4%1.9%2.0%2.1%
Op Inc Chg LTM27.8%10.1%17.5%18.7%13.5%13.1%15.5%
Op Inc Chg 3Y Avg19.9%6.7%8.2%-10.0%5.3%1.7%6.0%
Op Mgn LTM-33.2%18.7%20.0%9.5%22.2%20.4%19.4%
Op Mgn 3Y Avg-52.5%18.2%18.9%9.7%22.1%19.8%18.6%
QoQ Delta Op Mgn LTM2.4%0.4%0.6%2.0%0.7%-0.0%0.6%
CFO/Rev LTM4.4%19.7%19.6%9.7%21.8%26.8%19.7%
CFO/Rev 3Y Avg-36.5%19.6%19.0%6.9%23.8%26.4%19.3%
FCF/Rev LTM4.0%16.0%17.6%6.1%17.2%22.4%16.6%
FCF/Rev 3Y Avg-38.3%16.1%17.2%3.6%18.3%21.3%16.6%

Valuation

MASSTMOTDYBRKRADHRMedian
Name908 Devi.Thermo F.Teledyne.Bruker Agilent .Danaher  
Mkt Cap0.4257.329.19.750.2160.339.6
P/S5.95.44.52.76.86.35.7
P/Op Inc-17.929.022.329.030.630.729.0
P/EBIT-17.927.322.2-674.828.530.924.7
P/E-16.136.428.3-78.234.937.031.6
P/CFO135.427.622.728.231.223.427.9
Total Yield-6.2%3.0%3.5%-1.0%3.5%3.3%3.2%
Dividend Yield0.0%0.3%0.0%0.3%0.6%0.6%0.3%
FCF Yield 3Y Avg-11.5%3.2%4.1%1.2%3.0%3.2%3.1%
D/E0.00.20.10.20.10.20.1
Net D/E-0.20.10.10.20.00.10.1

Returns

MASSTMOTDYBRKRADHRMedian
Name908 Devi.Thermo F.Teledyne.Bruker Agilent .Danaher  
1M Rtn-16.8%2.4%1.3%14.3%4.8%1.5%1.9%
3M Rtn-7.1%13.4%-3.2%8.0%14.7%7.9%7.9%
6M Rtn36.2%54.2%2.2%43.2%57.0%33.6%39.7%
12M Rtn77.8%21.2%24.5%49.0%24.7%1.7%24.6%
3Y Rtn39.2%50.6%60.8%4.5%60.9%11.5%44.9%
1M Excs Rtn-13.5%5.0%3.1%17.0%6.7%5.4%5.2%
3M Excs Rtn-5.2%13.9%2.0%8.6%17.0%8.6%8.6%
6M Excs Rtn36.5%54.4%2.4%43.4%57.2%33.8%40.0%
12M Excs Rtn65.6%11.9%14.5%41.0%12.9%-7.1%13.7%
3Y Excs Rtn0.3%-10.6%-4.7%-57.1%1.0%-49.6%-7.7%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Product revenue4336404441
Service and contract revenue13121021
Total5648504742


Price Behavior

Price Behavior
Market Price$9.52 
Market Cap ($ Bil)0.4 
First Trading Date12/18/2020 
Distance from 52W High-26.0% 
   50 Days200 Days
DMA Price$11.14$8.61
DMA Trendupup
Distance from DMA-14.5%10.6%
 3M1YR
Volatility70.2%63.5%
Downside Capture313.47197.87
Upside Capture304.74237.30
Correlation (S&P 500)61.1%41.5%
MASS Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta4.293.102.632.311.611.44
Up Beta0.492.742.412.391.751.65
Down Beta5.596.135.402.460.890.56
Up Capture378%281%322%399%306%748%
Bmk +ve Days12182862130427
Stock +ve Days13243770127354
Down Capture392%176%90%150%137%112%
Bmk -ve Days10253664121325
Stock -ve Days9192756120379

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MASS
MASS77.4%63.5%1.14-
Sector ETF (XLV)21.5%17.0%0.968.5%
Equity (SPY)10.9%13.8%0.4940.8%
Gold (GLD)-8.2%29.0%-0.3027.4%
Commodities (DBC)28.8%21.5%1.07-7.3%
Real Estate (VNQ)11.2%14.2%0.506.9%
Bitcoin (BTCUSD)-29.6%43.7%-0.6918.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MASS
MASS-21.2%94.9%0.14-
Sector ETF (XLV)8.0%15.4%0.3319.9%
Equity (SPY)11.0%17.3%0.4631.8%
Gold (GLD)14.5%19.2%0.6011.8%
Commodities (DBC)6.8%19.6%0.245.3%
Real Estate (VNQ)1.1%19.0%-0.0527.5%
Bitcoin (BTCUSD)-0.0%51.4%0.1817.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MASS
MASS-14.9%92.5%0.09-
Sector ETF (XLV)12.1%16.8%0.5919.3%
Equity (SPY)14.9%18.0%0.7031.6%
Gold (GLD)10.9%16.6%0.5311.4%
Commodities (DBC)7.2%18.2%0.316.3%
Real Estate (VNQ)5.8%20.7%0.2426.9%
Bitcoin (BTCUSD)57.1%66.3%0.9717.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity2.5 Mil
Short Interest: % Change Since 10152026-6.0%
Average Daily Volume0.4 Mil
Days-to-Cover Short Interest7.1 days
Basic Shares Quantity41.1 Mil
Short % of Basic Shares6.2%

Earnings Returns History

Updated 11/19/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/10/2026-13.2%-20.2% 
8/11/202613.7%15.8%10.1%
5/6/202613.7%7.9%24.4%
3/3/2026-4.4%-3.7%-7.4%
11/10/2025-13.3%-25.7%-10.8%
8/5/2025-2.8%-1.4%-15.3%
5/13/2025-18.8%-16.8%27.1%
3/4/202596.0%52.5%105.6%
...
SUMMARY STATS   
# Positive12811
# Negative121612
Median Positive12.4%9.0%24.4%
Median Negative-12.8%-10.4%-13.1%
Max Positive96.0%52.5%105.6%
Max Negative-22.0%-38.2%-44.2%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/10/2026-13.2%-20.2% 
8/11/202613.7%15.8%10.1%
5/6/202613.7%7.9%24.4%
3/3/2026-4.4%-3.7%-7.4%
11/10/2025-13.3%-25.7%-10.8%
8/5/2025-2.8%-1.4%-15.3%
5/13/2025-18.8%-16.8%27.1%
3/4/202596.0%52.5%105.6%
11/12/2024-19.3%-34.8%-37.6%
8/6/20240.0%-8.2%-19.4%
4/30/2024-1.0%-2.3%9.6%
3/5/2024-3.7%-7.9%-8.6%
11/7/20234.1%-4.4%24.9%
8/8/202322.0%13.1%6.1%
5/9/20236.2%2.5%31.7%
3/7/20232.9%-12.3%-6.9%
11/14/2022-22.0%-38.2%-44.2%
8/9/2022-12.4%-9.0%-9.7%
5/10/202214.4%3.4%2.3%
3/7/202215.1%10.1%27.9%
1/10/2022-4.4%-11.8%-22.4%
11/4/202111.0%-2.3%-30.0%
8/4/20218.0%1.1%16.5%
5/13/2021-16.5%-16.3%-7.3%
SUMMARY STATS   
# Positive12811
# Negative121612
Median Positive12.4%9.0%24.4%
Median Negative-12.8%-10.4%-13.1%
Max Positive96.0%52.5%105.6%
Max Negative-22.0%-38.2%-44.2%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/10/202610-Q
06/30/202608/11/202610-Q
03/31/202605/06/202610-Q
12/31/202503/09/202610-K
09/30/202511/10/202510-Q
06/30/202508/05/202510-Q
03/31/202505/13/202510-Q
12/31/202403/07/202510-K
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202405/03/202410-Q
12/31/202303/08/202410-K
09/30/202311/07/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/15/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/10/202610-Q
06/30/202608/11/202610-Q
03/31/202605/06/202610-Q
12/31/202503/09/202610-K
09/30/202511/10/202510-Q
06/30/202508/05/202510-Q
03/31/202505/13/202510-Q
12/31/202403/07/202510-K
09/30/202411/12/202410-Q
06/30/202408/06/202410-Q
03/31/202405/03/202410-Q
12/31/202303/08/202410-K
09/30/202311/07/202310-Q
06/30/202308/08/202310-Q
03/31/202305/09/202310-Q
12/31/202203/15/202310-K
09/30/202211/14/202210-Q
06/30/202208/09/202210-Q
03/31/202205/10/202210-Q
12/31/202103/11/202210-K
09/30/202111/04/202110-Q
06/30/202108/04/202110-Q
03/31/202105/13/202110-Q
12/31/202003/31/202110-K
09/30/202012/18/2020424B4

Recent Forward Guidance

Updated 11/11/2026

Latest: Q3 2026 Earnings Reported 11/10/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported68.50 Mil69.25 Mil70.00 Mil0.4% RaisedGuidance: 69.00 Mil for 2026
2026 Revenue GrowthReported22.0%23.5%25.0% 0.5%RaisedGuidance: 23.0% for 2026


Prior: Q2 2026 Earnings Reported 8/11/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported68.00 Mil69.00 Mil70.00 Mil  RaisedGuidance: 68.50 Mil for 2026
2026 Revenue GrowthReported21.0%23.0%25.0% 1.0%RaisedGuidance: 22.0% for 2026

Q1 2026 Earnings Reported 5/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported67.00 Mil68.50 Mil70.00 Mil3.8% RaisedGuidance: 66.00 Mil for 2026
2026 Revenue GrowthReported19.0%22.0%25.0% 4.5%RaisedGuidance: 17.5% for 2026

Q4 2025 Earnings Reported 3/3/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported64.50 Mil66.00 Mil67.50 Mil20.0% Higher NewActual: 55.00 Mil for 2025
2026 Revenue GrowthReported15.0%17.5%20.0% 2.5%Higher NewActual: 15.0% for 2025

Insider Activity

Updated 11/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Brown, Christopher DDirectSell1106202610.9530,000328,5008,492,371Form
2Brown, Christopher DDirectSell1009202611.8930,000356,7008,864,697Form
3Griffith, Joseph H IVChief Financial OfficerDirectSell1008202613.035,00065,1501,517,956Form
4Awm, Investment Company, Inc Limited PartnershipSell1001202611.5218,000207,32254,557,678Form
5Awm, Investment Company, Inc Limited PartnershipSell925202611.3624,000272,62654,011,368Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Brown, Christopher DDirectSell1106202610.9530,000328,5008,492,371Form
2Brown, Christopher DDirectSell1009202611.8930,000356,7008,864,697Form
3Griffith, Joseph H IVChief Financial OfficerDirectSell1008202613.035,00065,1501,517,956Form
4Awm, Investment Company, Inc Limited PartnershipSell1001202611.5218,000207,32254,557,678Form
5Awm, Investment Company, Inc Limited PartnershipSell925202611.3624,000272,62654,011,368Form
6Awm, Investment Company, Inc Limited PartnershpSell925202611.251,00011,25053,502,446Form
7Kenneweg, JohnSVP, Sales & Product MarketingDirectSell917202610.225,25753,727590,552Form
8Kenneweg, JohnSVP, Sales & Product MarketingDirectSell917202610.1121,399216,344584,196Form
9Kenneweg, JohnSVP, Sales & Product MarketingDirectSell917202610.001,00010,000577,840Form
10Brown, Christopher DDirectSell904202610.5830,000317,4008,205,414Form
11Griffith, Joseph H IVChief Financial OfficerDirectSell827202610.9511,459125,4761,330,392Form
12Awm, Investment Company, Inc Limited PartnershipSell824202610.6141,578441,15950,715,303Form
13Awm, Investment Company, Inc Limited PartnershipSell824202610.528,42288,63850,742,791Form
14Knopp, Kevin JPresident and CEODirectSell817202610.3520,000207,0005,754,269Form
15Knopp, Kevin JPresident and CEODirectSell817202610.067,62276,6775,794,238Form
16Knopp, Kevin JPresident and CEODirectSell812202610.072,74727,6625,876,751Form
17Brown, Christopher DDirectSell81220269.238,35877,1447,435,310Form
18Knopp, Kevin JPresident and CEODirectSell81220269.90145,9181,444,3305,803,699Form
19Brown, Christopher DDirectSell81220269.039,44285,2617,349,671Form
20Knopp, Kevin JPresident and CEODirectSell81220269.063483,1536,634,230Form
21Awm, Investment Company, Inc Limited PartnershipSell80620268.3650,000417,76540,354,202Form
22Knopp, Kevin JPresident and CEODirectSell70720269.072222,0146,644,709Form
23Brown, Christopher DDirectSell70720269.022,20019,8447,607,098Form
24Brown, Christopher DDirectSell70220268.8420,000176,8007,474,742Form
25Knopp, Kevin JPresident and CEODirectSell63020269.092,79825,4346,661,379Form
26Knopp, Kevin JPresident and CEODirectSell62520269.1016,388149,1316,694,169Form
27Knopp, Kevin JPresident and CEODirectSell62520269.1440,535370,4906,873,381Form
28Brown, Christopher DDirectSell62520269.049,90089,4967,824,653Form
29Knopp, Kevin JPresident and CEODirectSell62520269.063,42231,0037,180,467Form
30Awm, Investment Company, Inc Limited PartnershipsSell62420269.003,05027,46343,937,964Form
31Awm, Investment Company, Inc Limited PartnershipsSell62420268.994,66841,96543,896,579Form
32Awm, Investment Company, Inc Limited PartnershipSell60420268.9739,782356,85643,842,261Form
33Brown, Christopher DDirectSell60420268.7320,000174,6007,643,630Form
34Awm, Investment Company, Inc Limited PartnershipSell60420268.952,50022,37544,099,093Form
35Brown, Christopher DDirectSell52920269.0030,000270,0008,060,031Form
36Awm, Investment Company, Inc Limited PartnershipSell52920268.66170,4421,475,92542,688,876Form
37Griffith, Joseph H IVChief Financial OfficerDirectSell52920269.036,94062,6681,200,593Form
38Awm, Investment Company, Inc Limited PartnershipSell52920268.2516,500136,16642,089,292Form
39Awm, Investment Company, Inc Limited PartnershipSell51320268.255,00041,25742,220,062Form
40Kenneweg, JohnSVP, Sales & Product MarketingDirectSell51120268.1118,255148,048468,628Form
41Awm, Investment Company, Inc Limited PartnershipSell50820268.203,02524,80541,998,063Form
42Awm, Investment Company, Inc Limited PartnershipSell50820268.2012,819105,17042,044,392Form
43Awm, Investment Company, Inc Limited PartnershipSell50820268.0562,365502,15541,366,999Form
44Brown, Christopher DDirectSell50720267.2320,000144,6006,691,792Form
45Kenneweg, JohnSVP, Sales & Product MarketingDirectSell50420266.837,78753,185519,346Form
46McCallion, Kevin JSVP, Products and ProductionDirectSell41420267.012,69318,878314,924Form
47Brown, Christopher DDirectSell41020267.0717,578124,2766,685,102Form
48McCallion, Kevin JSVP, Products and ProductionDirectSell41020267.035,42038,103315,823Form
49Brown, Christopher DDirectSell41020267.047,39252,0406,780,484Form
50McCallion, Kevin JSVP, Products and ProductionDirectSell41020267.0518,580130,989316,721Form
51Brown, Christopher DDirectSell41020267.0515,030105,9626,842,229Form
52McCallion, Kevin JSVP, Products and ProductionDirectSell30420267.00749314,426Form
53Knopp, Kevin JPresident and CEODirectSell20320266.1834,764214,8424,919,082Form
54Griffith, Joseph H IVChief Financial OfficerDirectSell20320266.1823,175143,222864,557Form

Investor Activity (13F)

Updated Nov 19, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Light Asset Management, LLC$37.2 Mil3.3%35ADD +25.6%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Light Asset Management, LLC$37.2 Mil3.3%35ADD +25.6%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
First Light Asset Management, LLC$37.2 Mil3.3%35ADD +25.6%13F
Core Cache Last Updated: 11/18/2026